9 January 2026
1 min read

PVH stock slips as Supreme Court tariff decision hangs over retailers — what traders watch next

PVH stock slips as Supreme Court tariff decision hangs over retailers — what traders watch next

New York, Jan 9, 2026, 14:33 EST — Regular session

  • PVH shares fell about 4% in afternoon trade, bucking a higher consumer-discretionary sector
  • U.S. Supreme Court said it would not issue a tariffs ruling on Friday; next opinions are due Jan. 14
  • PVH has flagged tariffs as a profit headwind, adding focus to any change in trade policy

PVH Corp shares fell 4.4% to $65.32 on Friday afternoon, extending a choppy week for the Calvin Klein and Tommy Hilfiger owner.

The drop comes as investors wait on U.S. tariff policy, after the Supreme Court said it would not rule on the legality of President Donald Trump’s sweeping tariffs on Friday and is expected to issue its next decisions on Jan. 14. (Reuters)

That matters for import-heavy brands because tariff outcomes can swing costs quickly, while the broader market was leaning risk-on after a softer December U.S. jobs report kept rate-cut expectations in play. “This is a report that’s somewhat within the range of expectations of investors, so they’re not reacting,” Mark Hackett, chief market strategist at Nationwide, told Reuters. (Reuters)

PVH has already put numbers around the issue. The company said in its most recent quarterly update that its 2025 outlook included an unmitigated tariffs hit of about $65 million to EBIT, or roughly $1.05 per share, partly offset by mitigation actions. (Pvh)

A separate SEC filing on Thursday showed interim CFO Melissa A. Stone reported holding 15,410 PVH shares directly, including restricted stock units, plus stock held through a 401(k) plan. (SEC)

PVH’s slide stood out against a firmer tape: the consumer discretionary sector ETF XLY was up about 1.1%, while the retail ETF XRT was little changed.

There are risks to both sides of the trade-policy bet. Even investors leaning toward tariff relief have cautioned that a court ruling may not translate into immediate changes on the ground, depending on what the administration does next. (Barron’s)

Near term, traders will watch for any tariff-related read-through across apparel and retail, while earnings calendars expect PVH’s next results around late March. The sharper catalyst is Jan. 14, when the Supreme Court is due to return with more opinions. (Zacks)

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Dell Technologies stock rebounds as DELL snaps a four-day slide — what’s driving the move
Previous Story

Dell Technologies stock rebounds as DELL snaps a four-day slide — what’s driving the move

Uber stock slides nearly 3% as CES robotaxi push puts costs back in focus
Next Story

Uber stock slides nearly 3% as CES robotaxi push puts costs back in focus

Go toTop